Condition: Relapsed Advanced Lymphomas · Sponsor: Aurigene Discovery Technologies Limited
An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced lymphomas will be done to assess AUR108 safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose.
This description comes directly from the study's public registry record.
Suchit Kumbhare · +918104730078 · suchit_k@aurigene.com
Suresh Oduru · 9866225593 · suresh_o@aurigene.com
Always discuss trial participation with your own doctor first.
| Omega Cancer Hospitals | Visakhapatnam, Andhra Pradesh, India | Recruiting |
| Post Graduate Institute of Medical Education & Research, | Chandigarh, Chandigarh, India | Recruiting |
| Cellcure Care Cancer Pvt Ltd | Ahmedabad, Gujarat, India | Recruiting |
| HCC Happiness Care and Cure Multispeciality Hospital | Ahmedabad, Gujarat, India | Recruiting |
| Shankus Hospital Pvt. Ltd. | Ahmedabad, Gujarat, India | Recruiting |
| Unique Hospital | Surat, Gujarat, India | Recruiting |
| Kiran Multi Speciality Hospital | Surat, Gujarat, India | Recruiting |
| Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences | Rohtak, Haryana, India | Recruiting |
| Super Specialty Hospital (G.M.C) Srinagar | Srinagar, Jammu and Kashmir, India | Recruiting |
| KLES Dr Prabhakar Kore Hospital and MRC | Belagavi, Karnataka, India | Recruiting |
| Amrita Institute of Medical Sciences (AIMS) | Kochi, Kerala, India | Recruiting |
| Sujan Surgical Cancer Hospital and Amravati Cancer Foundation | Amravati, Maharashtra, India | Recruiting |
+ 15 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05984147